Caitlin Fierheller, PhD

Profile

I joined the Women’s Precision Prevention (WPP) team with Prof Ranjit Manchanda as a postdoctoral research associate in February 2023. I am currently working across clinical trials in the WPP team which focus on population-based genetic testing, targeted screening, cancer prevention (including surgical) and health economics. I am a co-investigator on the PROTECT-C (Population based germline testing for early detection and prevention of cancer) and DETECT-2 (Direct to patient testing at cancer diagnosis for precision prevention-2). I also work on the Jewish Hereditary Cancer Review, PRESCORES (Preventing Endometrial Cancers: Comparing Risk-Reducing Strategies), PROTECTOR (Prevention ovarian cancer through early excision of tubes and late ovarian removal), and other studies.

I completed my PhD in Human Genetics at McGill University, Montreal, Canada in 2023. My research focused on the molecular genetics of germline potentially pathogenic variants in DNA repair pathway genes in familial ovarian cancer. I obtained my BSc in 2016 in Genetics and Biochemistry from Western University, London, Canada.

Research

Research Interests:

Cancer prevention

Cancer genetics

Population-based genetic testing

Publications

• Fierheller C, Sarig K, Oxley S et al. (2024). BRCA awareness and testing experience in the UK Jewish population: A qualitative study. nameOfConference

  
  

  DOI: 10.1016/j.ygyno.2024.07.238

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100560
• Fierheller C, Gootzen T, Kalra A et al. (2024). BRCA1 and BRCA2 information provision online: An occasion for improvement. nameOfConference

  
  

  DOI: 10.1016/j.ygyno.2024.07.234

  
  

  QMRO: qmroHref
• Manchanda R, Wei X, Sun L et al. (2024). Cost-effectiveness analysis of cancer susceptibility gene-specific prevention strategies for ovarian and breast cancer. nameOfConference

  
  

  DOI: 10.1016/j.ygyno.2024.07.233

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100488
• Fierheller C, Sun L, Wei X et al. (2024). Population-based BRCA1 and BRCA2 genetic testing is cost-effective in Canada. nameOfConference

  
  

  DOI: 10.1016/j.ygyno.2024.07.067

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/100552
• Kalra A, Ganesan S, Sia J et al. (2024). EV186/#1233  Patient-related outcomes of mainstreaming genetic testing – a systematic review and meta-analysis. E-Poster Viewing Abstracts

  
  

  DOI: 10.1136/ijgc-2024-igcs.305

  
  

  QMRO: qmroHref
• Sun L, Wei X, Fierheller CT et al. (2024). Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada. nameOfConference

  
  

  DOI: 10.1001/jamanetworkopen.2024.32725

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/98325
• Manchanda R (2024). Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis. nameOfConference

  
  

  DOI: 10.3390/cancers16132324

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/97698
• Manchanda R, Sun L, Wei X et al. (2024). Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. nameOfConference

  
  

  DOI: 10.6004/jnccn.2023.7331

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95917
• Oxley S, Manchanda R (2024). BRCA awareness and testing experience in the UK Jewish population: a qualitative study. nameOfConference

  
  

  DOI: 10.1136/jmg-2023-109576

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95916
• Oxley S, Manchanda R (2024). Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D. nameOfConference

  
  

  DOI: 10.3390/cancers16071358

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/95918